TYPTF (Entropy Neurodynamics) Other Operating Expense: $0.03 Mil (TTM As of Dec. 2025)


What is Entropy Neurodynamics Other Operating Expense?

Entropy Neurodynamics TYPTF Other Operating Expense is $0.03 Mil as of Dec. 2025. The stock has 5 warning signs investors should review.

Entropy Neurodynamics's Other Operating Expense for the six months ended in Dec. 2025 was $0.01 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 was $0.03 Mil.

Entropy Neurodynamics's quarterly Other Operating Expense increased from Dec. 2024 ($0.01 Mil) to Jun. 2025 ($0.02 Mil) but then declined from Jun. 2025 ($0.02 Mil) to Dec. 2025 ($0.01 Mil).

Entropy Neurodynamics's annual Other Operating Expense declined from Jun. 2022 ($1.41 Mil) to Jun. 2023 ($1.33 Mil) and declined from Jun. 2023 ($1.33 Mil) to Jun. 2025 ($0.03 Mil).

Entropy Neurodynamics Other Operating Expense Historical Data

* Premium members only.

The historical data trend for Entropy Neurodynamics's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Entropy Neurodynamics Other Operating Expense Chart

Entropy Neurodynamics Annual Data
Trend Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun25
Other Operating Expense
Get a 7-Day Free Trial 0.41 0.97 1.41 1.33 0.03

Entropy Neurodynamics Semi-Annual Data
Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Dec24 Jun25 Dec25
Other Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.10 0.18 0.01 0.02 0.01

Entropy Neurodynamics Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.03 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Other Operating Expense of $0.03 Mil mean?
Entropy Neurodynamics (TYPTF) has a Other Operating Expense of $0.03 Mil as of Dec. 2025. Other operating expenses that a company records on its income statement. View historical data on Entropy Neurodynamics and its competitors.
Is Entropy Neurodynamics' Other Operating Expense too high?
Entropy Neurodynamics' current Other Operating Expense is $0.03 Mil.
How does Entropy Neurodynamics' Other Operating Expense compare to VRTX and REGN?
Entropy Neurodynamics' Other Operating Expense of $0.03 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Operating Expense for a Biotechnology company?
A good Other Operating Expense depends on the Biotechnology industry context. However, Other Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Operating Expense mean?
A high Other Operating Expense can signal that a stock is expensive relative to its fundamentals. Other operating expenses that a company records on its income statement. View historical data on Entropy Neurodynamics and its competitors. Entropy Neurodynamics's current Other Operating Expense is $0.03 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Entropy Neurodynamics stock overvalued right now?
Based on GuruFocus' analysis, Entropy Neurodynamics (TYPTF) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.01, compared to a current price of $0.01 — trading 12% above its estimated fair value. The current Other Operating Expense is $0.03 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Operating Expense calculated?
Other Operating Expense is calculated from a company's financial statements. For Entropy Neurodynamics (TYPTF), the current Other Operating Expense is $0.03 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Entropy Neurodynamics Business Description

Other Exchanges ENP:Australia
Address 117 Camberwell Road,, Hawthorn East, Suite 1.01, Camberwell, Melbourne, VIC, AUS, 3123
Entropy Neurodynamics Ltd is a clinical-stage biotechnology company focused on developing proprietary, novel formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs. The company's lead program is TRP-8803. TRP-8803 is a proprietary formulation of IV-infused psilocin (the active metabolite of psilocybin) with potential to alleviate numerous shortcomings of oral psilocybin including: significantly reducing the time to onset of the psychedelic state, controlling the depth and duration of the psychedelic experience, and reducing the overall duration of the intervention to a commercially feasible timeframe.